PDF(Pubmed)
Abstract：
BACKGROUND: Testicular cancer and Hodgkin\'s lymphoma are prevalent malignancies among young males aged 20 to 39. The incidence of testicular cancer and lymphoma has risen in recent years, with orchiectomy often followed by adjuvant chemotherapy as the primary treatment for testicular cancer and chemotherapy for lymphoma. Chemotherapy has been associated with an increased risk of aneuploidy and reduced fertility.
METHODS: This systematic review included seven studies, both case-control and longitudinal prospective designs, from the PubMed, Embase, and Cochrane Library databases. The screening process was conducted using the online tool covidence.org.
RESULTS: The study outcomes indicate varied impacts of chemotherapy on aneuploidy rates. An increase in the aneuploidy rates, notably for the sex chromosomes, immediately post-treatment was a common trend, followed by a decline in pretreatment values.
CONCLUSIONS: This systematic review presents the effects of chemotherapy on the aneuploidy rates of testicular cancer and Hodgkin\'s lymphoma patients, with a decrease post-treatment. The findings underscore the need for larger, well-designed studies with a longer study period.
METHODS: This systematic review included seven studies, both case-control and longitudinal prospective designs, from the PubMed, Embase, and Cochrane Library databases. The screening process was conducted using the online tool covidence.org.
RESULTS: The study outcomes indicate varied impacts of chemotherapy on aneuploidy rates. An increase in the aneuploidy rates, notably for the sex chromosomes, immediately post-treatment was a common trend, followed by a decline in pretreatment values.
CONCLUSIONS: This systematic review presents the effects of chemotherapy on the aneuploidy rates of testicular cancer and Hodgkin\'s lymphoma patients, with a decrease post-treatment. The findings underscore the need for larger, well-designed studies with a longer study period.
摘要：
背景：睾丸癌和霍奇金淋巴瘤是20至39岁年轻男性中普遍存在的恶性肿瘤。近年来睾丸癌和淋巴瘤的发病率呈上升趋势,睾丸切除术后通常进行辅助化疗作为睾丸癌和淋巴瘤化疗的主要治疗方法。化疗与非整倍性风险增加和生育能力降低有关。
方法：本系统综述包括7项研究，病例对照和纵向前瞻性设计，从PubMed,Embase,和Cochrane图书馆数据库。筛选过程是使用在线工具covidence.org进行的。
结果：研究结果表明化疗对非整倍体率的不同影响。非整倍体率的增加，特别是对于性染色体，立即治疗后是一个普遍的趋势，其次是预处理值的下降。
结论：本系统综述介绍了化疗对睾丸癌和霍奇金淋巴瘤患者非整倍体率的影响。随着治疗后的减少。调查结果强调了对更大，精心设计的研究与更长的研究时间。
方法：本系统综述包括7项研究，病例对照和纵向前瞻性设计，从PubMed,Embase,和Cochrane图书馆数据库。筛选过程是使用在线工具covidence.org进行的。
结果：研究结果表明化疗对非整倍体率的不同影响。非整倍体率的增加，特别是对于性染色体，立即治疗后是一个普遍的趋势，其次是预处理值的下降。
结论：本系统综述介绍了化疗对睾丸癌和霍奇金淋巴瘤患者非整倍体率的影响。随着治疗后的减少。调查结果强调了对更大，精心设计的研究与更长的研究时间。
